Cargando…

Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study

PURPOSE: A three-drug combination of cyclophosphamide, bortezomib, and dexamethasone (CVD) shows significant efficacy and manageable toxicity as induction therapy in patients with multiple myeloma. MATERIALS AND METHODS: In this phase II study, we enrolled 45 patients who achieved a very good partia...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Jongheon, Kim, Kihyun, Jung, Sung-Hoon, Yoon, Sung-Soo, Lee, Jae Hoon, Kim, Jin Seok, Shin, Ho-Jin, Bang, Soo-Mee, Sohn, Sang Kyun, Suh, Cheolwon, Yoon, Dok Hyun, Kong, Sun-Young, Min, Chang-Ki, Eom, Hyeon-Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101807/
https://www.ncbi.nlm.nih.gov/pubmed/36397235
http://dx.doi.org/10.4143/crt.2022.952
_version_ 1785025586058493952
author Jung, Jongheon
Kim, Kihyun
Jung, Sung-Hoon
Yoon, Sung-Soo
Lee, Jae Hoon
Kim, Jin Seok
Shin, Ho-Jin
Bang, Soo-Mee
Sohn, Sang Kyun
Suh, Cheolwon
Yoon, Dok Hyun
Kong, Sun-Young
Min, Chang-Ki
Eom, Hyeon-Seok
author_facet Jung, Jongheon
Kim, Kihyun
Jung, Sung-Hoon
Yoon, Sung-Soo
Lee, Jae Hoon
Kim, Jin Seok
Shin, Ho-Jin
Bang, Soo-Mee
Sohn, Sang Kyun
Suh, Cheolwon
Yoon, Dok Hyun
Kong, Sun-Young
Min, Chang-Ki
Eom, Hyeon-Seok
author_sort Jung, Jongheon
collection PubMed
description PURPOSE: A three-drug combination of cyclophosphamide, bortezomib, and dexamethasone (CVD) shows significant efficacy and manageable toxicity as induction therapy in patients with multiple myeloma. MATERIALS AND METHODS: In this phase II study, we enrolled 45 patients who achieved a very good partial response (VGPR) or partial response (PR) after autologous stem cell transplantation (ASCT) and evaluated the efficacy and toxicity of CVD consolidation. CVD consolidation comprised three cycles of cyclophosphamide 300 mg/m(2) orally on days 1, 8, and 15, and bortezomib 1.3 mg/m(2) subcutaneously on days 1, 8, 15, and 22, along with dexamethasone 20 mg orally or intravenously on days 1 and 2, 8 and 9, 15 and 16, and 22 and 23. RESULTS: At enrollment, 39 patients (86.7%) showed VGPR, and nine (13.3%) presented with PR. Nineteen patients (45.2%) achieved a complete response or better as their best response after the end of consolidation. Overall, 22 of 42 patients (52.4%) experienced an improved response status with CVD consolidation. Three-year overall survival and progression-free survival rates were 89.0% and 42.7%, respectively. The most common non-hematologic toxicities were peripheral neuropathy and infection (20.5%), with no grade ≥ 3 neuropathy observed. CONCLUSION: These results showed that CVD consolidation therapy improved the response with reasonable toxicity in patients with residual disease after ASCT. This trial was registered with the Clinical Research Information Service, Republic of Korea (KCT0001327).
format Online
Article
Text
id pubmed-10101807
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Korean Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-101018072023-04-15 Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study Jung, Jongheon Kim, Kihyun Jung, Sung-Hoon Yoon, Sung-Soo Lee, Jae Hoon Kim, Jin Seok Shin, Ho-Jin Bang, Soo-Mee Sohn, Sang Kyun Suh, Cheolwon Yoon, Dok Hyun Kong, Sun-Young Min, Chang-Ki Eom, Hyeon-Seok Cancer Res Treat Original Article PURPOSE: A three-drug combination of cyclophosphamide, bortezomib, and dexamethasone (CVD) shows significant efficacy and manageable toxicity as induction therapy in patients with multiple myeloma. MATERIALS AND METHODS: In this phase II study, we enrolled 45 patients who achieved a very good partial response (VGPR) or partial response (PR) after autologous stem cell transplantation (ASCT) and evaluated the efficacy and toxicity of CVD consolidation. CVD consolidation comprised three cycles of cyclophosphamide 300 mg/m(2) orally on days 1, 8, and 15, and bortezomib 1.3 mg/m(2) subcutaneously on days 1, 8, 15, and 22, along with dexamethasone 20 mg orally or intravenously on days 1 and 2, 8 and 9, 15 and 16, and 22 and 23. RESULTS: At enrollment, 39 patients (86.7%) showed VGPR, and nine (13.3%) presented with PR. Nineteen patients (45.2%) achieved a complete response or better as their best response after the end of consolidation. Overall, 22 of 42 patients (52.4%) experienced an improved response status with CVD consolidation. Three-year overall survival and progression-free survival rates were 89.0% and 42.7%, respectively. The most common non-hematologic toxicities were peripheral neuropathy and infection (20.5%), with no grade ≥ 3 neuropathy observed. CONCLUSION: These results showed that CVD consolidation therapy improved the response with reasonable toxicity in patients with residual disease after ASCT. This trial was registered with the Clinical Research Information Service, Republic of Korea (KCT0001327). Korean Cancer Association 2023-04 2022-11-16 /pmc/articles/PMC10101807/ /pubmed/36397235 http://dx.doi.org/10.4143/crt.2022.952 Text en Copyright © 2023 by the Korean Cancer Association https://creativecommons.org/licenses/by-nc/4.0/This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Jung, Jongheon
Kim, Kihyun
Jung, Sung-Hoon
Yoon, Sung-Soo
Lee, Jae Hoon
Kim, Jin Seok
Shin, Ho-Jin
Bang, Soo-Mee
Sohn, Sang Kyun
Suh, Cheolwon
Yoon, Dok Hyun
Kong, Sun-Young
Min, Chang-Ki
Eom, Hyeon-Seok
Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study
title Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study
title_full Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study
title_fullStr Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study
title_full_unstemmed Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study
title_short Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study
title_sort cyclophosphamide, bortezomib, and dexamethasone consolidation in patients with multiple myeloma after stem cell transplantation: the kmm130 study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101807/
https://www.ncbi.nlm.nih.gov/pubmed/36397235
http://dx.doi.org/10.4143/crt.2022.952
work_keys_str_mv AT jungjongheon cyclophosphamidebortezomibanddexamethasoneconsolidationinpatientswithmultiplemyelomaafterstemcelltransplantationthekmm130study
AT kimkihyun cyclophosphamidebortezomibanddexamethasoneconsolidationinpatientswithmultiplemyelomaafterstemcelltransplantationthekmm130study
AT jungsunghoon cyclophosphamidebortezomibanddexamethasoneconsolidationinpatientswithmultiplemyelomaafterstemcelltransplantationthekmm130study
AT yoonsungsoo cyclophosphamidebortezomibanddexamethasoneconsolidationinpatientswithmultiplemyelomaafterstemcelltransplantationthekmm130study
AT leejaehoon cyclophosphamidebortezomibanddexamethasoneconsolidationinpatientswithmultiplemyelomaafterstemcelltransplantationthekmm130study
AT kimjinseok cyclophosphamidebortezomibanddexamethasoneconsolidationinpatientswithmultiplemyelomaafterstemcelltransplantationthekmm130study
AT shinhojin cyclophosphamidebortezomibanddexamethasoneconsolidationinpatientswithmultiplemyelomaafterstemcelltransplantationthekmm130study
AT bangsoomee cyclophosphamidebortezomibanddexamethasoneconsolidationinpatientswithmultiplemyelomaafterstemcelltransplantationthekmm130study
AT sohnsangkyun cyclophosphamidebortezomibanddexamethasoneconsolidationinpatientswithmultiplemyelomaafterstemcelltransplantationthekmm130study
AT suhcheolwon cyclophosphamidebortezomibanddexamethasoneconsolidationinpatientswithmultiplemyelomaafterstemcelltransplantationthekmm130study
AT yoondokhyun cyclophosphamidebortezomibanddexamethasoneconsolidationinpatientswithmultiplemyelomaafterstemcelltransplantationthekmm130study
AT kongsunyoung cyclophosphamidebortezomibanddexamethasoneconsolidationinpatientswithmultiplemyelomaafterstemcelltransplantationthekmm130study
AT minchangki cyclophosphamidebortezomibanddexamethasoneconsolidationinpatientswithmultiplemyelomaafterstemcelltransplantationthekmm130study
AT eomhyeonseok cyclophosphamidebortezomibanddexamethasoneconsolidationinpatientswithmultiplemyelomaafterstemcelltransplantationthekmm130study
AT cyclophosphamidebortezomibanddexamethasoneconsolidationinpatientswithmultiplemyelomaafterstemcelltransplantationthekmm130study